Results 161 to 170 of about 27,191 (241)

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review. [PDF]

Front Immunol
Yin HQ, Jin S, Fu Y, Zhu HL, Li XF.
europepmc   +1 more source

Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report. [PDF]

Case Rep Cardiol
Hamid S, Bennet R, Yao J, Wong J.
europepmc   +1 more source

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort. [PDF]

Ann Hematol
Mendicino F, Caridà G, Bruzzese A, Martino EA, Caserta S, Amodio N, Lucia E, Olivito V, Labanca C, Alvaro ME, Luciani F, Morabito F, Vigna E, Gentile M.   +13 more
europepmc   +1 more source

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review. [PDF]

Front Oncol
Al-Asa'd Y, Qasem N, Alshurafa A, Al-Farsi K, Yassin MA.   +4 more
europepmc   +1 more source

Spontaneous bacterial peritonitis in non-cirrhotic portal hypertension secondary to primary myelofibrosis: A rare case report. [PDF]

ILIVER
Pradana FR, Nuramalia LS, Maimunah U.
europepmc   +1 more source

Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis. [PDF]

J Patient Rep Outcomes
Cutts K, Cardellino A, Zhang S, Phiri K, Gelhorn H.   +4 more
europepmc   +1 more source

Prospects of Chimeric Antigen Receptor T-Cell Therapy in Myelofibrosis: From Immunopathogenesis to Therapeutic Strategies. [PDF]

Cancers (Basel)
Kong L, Fu C, Song L, Wang W, Ji M, Li F, Shi X, Chen W.   +7 more
europepmc   +1 more source

Cutaneous Extramedullary Hematopoiesis in Primary Myelofibrosis: A Case Report With Rapidly Fatal Outcome. [PDF]

Cureus
El Bouhmadi A, Baghad B, Rachadi H, Benhayoun FZ, Chiheb S.   +4 more
europepmc   +1 more source

Myelofibrosis

, 2020
openaire   +1 more source

Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Polepally AR, Goebel A, Patel M, Biesdorf C, Potluri J, Menon RM, Mensing S, Engelhardt B.   +7 more
europepmc   +1 more source